文献速递银屑病与炎症性皮肤病

局部钙调神经磷酸酶抑制剂治疗口腔扁平苔藓:系统评价与Meta分析

Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis.
PubMed 文献 · Br J Dermatol · 2019-07-15

短期(3-8周)治疗中,TCI(他克莫司、吡美莫司、环孢素)疗效与TCS相似,他克莫司局部不良事件发生率显著高于TCS,但全身不良事件少且不严重。

要点

  • 短期(3-8周)TCI治疗OLP疗效与TCS相似。
  • 他克莫司局部不良事件发生率显著高于TCS。
  • TCI全身不良事件少且不严重,血药浓度通常检测不到。

核心结论

  • TCI(他克莫司、吡美莫司、环孢素)短期治疗OLP疗效与TCS相似。
  • 他克莫司短期治疗局部不良事件发生率显著高于TCS。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Cochrane对照试验中心注册库、Web of Science及四个中文数据库(1950年至2018年5月)。

主要发现

  • 治疗OLP(3-8周),他克莫司、吡美莫司和环孢素疗效与TCS相似。
  • 他克莫司与TCS相比,3周至6个月复发率相似。
  • TCI血药浓度通常检测不到。
  • 他克莫司短期治疗局部不良事件发生率显著高于TCS。
  • 他克莫司和环孢素组出现少量全身不良事件,但不严重。

临床怎么用

  • OLP对TCS标准方案无应答时可考虑使用TCI。

局限性

  • 吡美莫司(3项试验)和环孢素(6项试验)证据有限。
  • 需进一步设计良好的试验评估TCI长期疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TCS (topical corticosteroids) are the first-line drug in the treatment of oral lichen planus (OLP). However, the value of topical calcineurin inhibitors (TCI) including tacrolimus, pimecrolimus and ciclosporin for OLP is still controversial. OBJECTIVES: To compare the efficacy and safety of TCI vs. TCS for OLP. METHODS: The authors searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science and four Chinese databases from 1950 to May 2018. The randomized controlled trials comparing TCI and TCS for OLP reported at least one of the following outcomes: improvement of clinical signs and/or symptoms, relapse, blood levels of TCI and adverse events. RESULTS: Twenty-one trials involving 965 patients were included in the analysis. For the treatment of OLP (3-8 weeks), TCI including tacrolimus, pimecrolimus and ciclosporin were similar to TCS in efficacy. Tacrolimus-TCS resulted in similar outcomes, with relapse at 3 weeks to 6 months. Blood levels of TCI were usually undetectable. In addition, tacrolimus showed a statistically higher incidence of local adverse events than TCS for short-term treatment. A few systemic adverse events occurred in the tacrolimus and ciclosporin groups, but they were not serious. CONCLUSIONS: The evidence for tacrolimus (n = 12), pimecrolimus (n = 3) and ciclosporin (n = 6) demonstrated that treatment with TCI may be an alternative approach when OLP does not respond to the standard protocols. Tacrolimus 0·1% should be the first drug of choice when selecting TCI for short-term treatment in recalcitrant OLP. Further well-designed trials are warranted to evaluate the long-term efficacy and safety of TCI. What's already known about this topic? The main topical drug for oral lichen planus (OLP) is topical corticosteroids (TCS). Patients with OLP who are not responsive to TCS or are at risk of adverse events from TCS need other alternative drugs. Topical calcineurin inhibitors (TCI), including tacrolimus, pimecrolimus and ciclosporin, have become a hot topic in a variety of mucocutaneous immune-mediated diseases. What does this study add? TCI including tacrolimus, pimecrolimus and ciclosporin were similar to TCS in efficacy for the short-term treatment of OLP. The local adverse events of tacrolimus were higher than with TCS. A few systemic adverse events were reported with TCI, but they were all tolerable and not serious. The limited evidence for pimecrolimus (three trials) and ciclosporin (six trials) requires further studies to evaluate the short-term and long-term efficacy and safety of TCI compared with TCS.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Sun SL, Liu JJ, Zhong B, et al. Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis. Br J Dermatol. 2019. PMID: 30903622. doi:10.1111/bjd.17898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。